Gotham Asset Management’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $11.5M | Buy |
|
|||||
|
2025
Q1 | $3.43M | Buy |
|
|||||
|
2024
Q4 | $780K | Sell |
|
|||||
|
2024
Q3 | $1.76M | Sell |
|
|||||
|
2024
Q2 | $5.27M | Buy |
|
|||||
|
2024
Q1 | $732K | Sell |
|
|||||
|
2023
Q4 | $730K | Buy |
|
|||||
|
2023
Q3 | $569K | Sell |
|
|||||
|
2023
Q2 | $510K | Sell |
|
|||||
|
2023
Q1 | $769K | Sell |
|
|||||
|
2022
Q4 | $935K | Buy |
|
|||||
|
2022
Q3 | $597K | Buy |
|
|||||
|
2022
Q2 | $545K | Sell |
|
|||||
|
2022
Q1 | $658K | Buy |
|
|||||
|
2021
Q4 | $218K | Buy |
|
|||||
|
2020
Q4 | – | Sell |
|
|||||
|
2020
Q3 | $1.8M | Buy |
|
|||||
|
2020
Q2 | $1.57M | Sell |
|
|||||
|
2020
Q1 | $1.66M | Sell |
|
|||||
|
2019
Q4 | $3.19M | Buy |
|
|||||
|
2019
Q3 | $1.26M | Buy |
|
|||||
|
2019
Q2 | $887K | Sell |
|
|||||
|
2019
Q1 | $1.7M | Buy |
|
|||||
|
2018
Q4 | $1.17M | Sell |
|
|||||
|
2018
Q3 | $2.9M | Buy |
|
|||||
|
2018
Q2 | $728K | Buy |
|